The effects of prolactin on the immune system, its relationship with the severity of COVID-19, and its potential immunomodulatory therapeutic effect
| dc.contributor.author | Rasmi, Yousef | |
| dc.contributor.author | Jalali, Ladan | |
| dc.contributor.author | Khalid, Saliha | |
| dc.contributor.author | Shokati, Ameneh | |
| dc.contributor.author | Tyagi, Poonam | |
| dc.contributor.author | Ozturk, Alpaslan | |
| dc.contributor.author | Nasimfar, Amir | |
| dc.date.accessioned | 2023-10-19T15:11:32Z | |
| dc.date.available | 2023-10-19T15:11:32Z | |
| dc.date.issued | 2023 | |
| dc.description.abstract | Prolactin (PRL) is an endocrine hormone secreted by the anterior pituitary gland that has a variety of physiological effects, including milk production, immune system regulation, and anti-inflammatory effects. Elevated levels of PRL have been found in several viral infections, including 2019 coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), a viral pathogen that has recently spread worldwide. PRL production is increased in SARS-CoV2 infection. While PRL can trigger the production of proinflammatory cytokines, it also has several anti-inflammatory effects that can reduce hyperinflammation. The exact mechanism of PRL's contribution to the severity of COVID-19 is unknown. The purpose of this review is to discuss the interaction between PRL and SARS-CoV2 infection and its possible association with the severity of COVID-19. | en_US |
| dc.description.sponsorship | The authors are grateful to the Department of Biochemistry, and Cellular and Molecular Medicine Institute, Urmia University of Medical Sciences, Urmia, Iran. Funding source, This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. | |
| dc.description.sponsorship | Department of Biochemistry; Urmia University of Medical Sciences, UMSU; Institute for Cellular and Molecular Medicine, University of Pretoria, ICMM | |
| dc.identifier.doi | 10.1016/j.cyto.2023.156253 | en_US |
| dc.identifier.issn | 1043-4666 | |
| dc.identifier.issn | 1096-0023 | |
| dc.identifier.scopus | 2-s2.0-85162171729 | en_US |
| dc.identifier.uri | https://doi.org/10.1016/j.cyto.2023.156253 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12469/5061 | |
| dc.language.iso | en | en_US |
| dc.publisher | Academic Press Ltd- Elsevier Science Ltd | en_US |
| dc.relation.ispartof | Cytokine | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.subject | Necrosis-Factor-Alpha | En_Us |
| dc.subject | Activated Macrophages | En_Us |
| dc.subject | Signal-Transduction | En_Us |
| dc.subject | Growth-Hormone | En_Us |
| dc.subject | C-Jun | En_Us |
| dc.subject | Expression | En_Us |
| dc.subject | Cell | En_Us |
| dc.subject | Receptor | En_Us |
| dc.subject | Mechanisms | En_Us |
| dc.subject | Release | En_Us |
| dc.subject | Necrosis-Factor-Alpha | |
| dc.subject | Activated Macrophages | |
| dc.subject | Signal-Transduction | |
| dc.subject | Growth-Hormone | |
| dc.subject | C-Jun | |
| dc.subject | Expression | |
| dc.subject | Prolactin | en_US |
| dc.subject | Cell | |
| dc.subject | SARS-CoV-2 | en_US |
| dc.subject | Receptor | |
| dc.subject | Severity | en_US |
| dc.subject | Mechanisms | |
| dc.subject | COVID-19 | en_US |
| dc.subject | Release | |
| dc.subject | Immunomodulatory effects | en_US |
| dc.title | The effects of prolactin on the immune system, its relationship with the severity of COVID-19, and its potential immunomodulatory therapeutic effect | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication | |
| gdc.author.id | Tyagi, Poonam/0000-0003-4495-4095 | |
| gdc.author.id | Khalid, Saliha/0000-0001-9480-6870 | |
| gdc.author.scopusid | 14060929900 | |
| gdc.author.scopusid | 56698868200 | |
| gdc.author.scopusid | 56708940700 | |
| gdc.author.scopusid | 57730012400 | |
| gdc.author.scopusid | 58316854600 | |
| gdc.author.scopusid | 57217135062 | |
| gdc.author.scopusid | 56999901700 | |
| gdc.author.wosid | nasimfar, amir/W-4753-2017 | |
| gdc.author.wosid | Rasmi, Yousef/H-1783-2017 | |
| gdc.author.wosid | Tyagi, Poonam/AGW-5417-2022 | |
| gdc.author.wosid | OZTURK, Alpaslan/AAV-6930-2021 | |
| gdc.bip.impulseclass | C4 | |
| gdc.bip.influenceclass | C5 | |
| gdc.bip.popularityclass | C4 | |
| gdc.coar.access | metadata only access | |
| gdc.coar.type | text::journal::journal article | |
| gdc.collaboration.industrial | false | |
| gdc.description.department | Kadir Has University | |
| gdc.description.departmenttemp | [Rasmi, Yousef; Jalali, Ladan] Urmia Univ Med Sci, Fac Med, Dept Biochem, Orumiyeh, Iran; [Khalid, Saliha] Kadir Has Univ, Sch Engn & Nat Sci, Dept Bioinformat & Genet, Cibali Campus Fatih, TR-34083 Istanbul, Turkiye; [Shokati, Ameneh] Univ Tehran Med Sci, Sch Adv Technol Med, Dept Appl Cell Sci, Tehran, Iran; [Shokati, Ameneh] Univ Tehran Med Sci, Neurosci Inst, Multiple Sclerosis Res Ctr, Tehran, Iran; [Tyagi, Poonam] Prince Sattam Bin Abdulaziz Univ, Coll Appl Med Sci, Dept Clin Lab Sci, Riyadh, Saudi Arabia; [Ozturk, Alpaslan] Hlth Sci Univ, Ankara Diskapi Yildirim Beyazit Training & Res Hos, Dept Med Biochem, Ankara, Turkiye; [Nasimfar, Amir] Urmia Univ Med Sci, Fac Med, Dept Pediat, Orumiyeh, Iran; [Jalali, Ladan] Urmia Univ Med Sci, Sch Med, Dept Biochem, Orumiyeh, Iran | en_US |
| gdc.description.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| gdc.description.scopusquality | Q2 | |
| gdc.description.startpage | 156253 | |
| gdc.description.volume | 169 | en_US |
| gdc.description.woscitationindex | Science Citation Index Expanded | |
| gdc.description.wosquality | Q2 | |
| gdc.identifier.openalex | W4379743204 | |
| gdc.identifier.pmid | 37320963 | en_US |
| gdc.identifier.wos | WOS:001054021200001 | en_US |
| gdc.index.type | WoS | |
| gdc.index.type | Scopus | |
| gdc.index.type | PubMed | |
| gdc.oaire.diamondjournal | false | |
| gdc.oaire.impulse | 22.0 | |
| gdc.oaire.influence | 3.086183E-9 | |
| gdc.oaire.isgreen | true | |
| gdc.oaire.keywords | Immunomodulatory effects | |
| gdc.oaire.keywords | Signal-Transduction | |
| gdc.oaire.keywords | C-Jun | |
| gdc.oaire.keywords | SARS-CoV-2 | |
| gdc.oaire.keywords | Anti-Inflammatory Agents | |
| gdc.oaire.keywords | COVID-19 | |
| gdc.oaire.keywords | Expression | |
| gdc.oaire.keywords | Severity | |
| gdc.oaire.keywords | Article | |
| gdc.oaire.keywords | Prolactin | |
| gdc.oaire.keywords | Activated Macrophages | |
| gdc.oaire.keywords | Release | |
| gdc.oaire.keywords | Immune System | |
| gdc.oaire.keywords | Growth-Hormone | |
| gdc.oaire.keywords | Mechanisms | |
| gdc.oaire.keywords | Necrosis-Factor-Alpha | |
| gdc.oaire.keywords | Humans | |
| gdc.oaire.keywords | RNA, Viral | |
| gdc.oaire.keywords | Cell | |
| gdc.oaire.keywords | Receptor | |
| gdc.oaire.popularity | 1.853236E-8 | |
| gdc.oaire.publicfunded | false | |
| gdc.openalex.collaboration | International | |
| gdc.openalex.fwci | 5.5279 | |
| gdc.openalex.normalizedpercentile | 0.97 | |
| gdc.openalex.toppercent | TOP 10% | |
| gdc.opencitations.count | 16 | |
| gdc.plumx.crossrefcites | 1 | |
| gdc.plumx.facebookshareslikecount | 20 | |
| gdc.plumx.mendeley | 39 | |
| gdc.plumx.newscount | 1 | |
| gdc.plumx.pubmedcites | 9 | |
| gdc.plumx.scopuscites | 20 | |
| gdc.scopus.citedcount | 20 | |
| gdc.wos.citedcount | 18 | |
| relation.isOrgUnitOfPublication | b20623fc-1264-4244-9847-a4729ca7508c | |
| relation.isOrgUnitOfPublication.latestForDiscovery | b20623fc-1264-4244-9847-a4729ca7508c |
Files
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- 5061.pdf
- Size:
- 769.11 KB
- Format:
- Adobe Portable Document Format
- Description:
- Tam Metin / Full Text